Poultry Pharmaceuticals Market - Global Forecast to 2029
商品番号 : SMB-72297
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年1月 |
| ページ数 | 425 |
| 図表数 | 556 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The poultry medicine/pharmaceuticals market is projected to reach USD 6.68 billion by 2029 from USD 5.01 billion in 2024, at a CAGR of 5.9% during the forecast period.
家禽用薬/医薬品市場は、2024年の50億1,000万米ドルから2029年までに66億8,000万米ドルに達すると予測されており、予測期間中のCAGRは5.9%です。
The increasing consumption of poultry and its products from the developing countries is mainly responsible for the growth of poultry medicine/pharmaceuticals market as it results in increased poultry farming practices. The rise in illnesses in poultry, especially Newcastle disease and Coccidiosis, leads to the need for vaccines, antibiotics, and immune boosters. Also, the growing attention towards food safety and the reduction of antibiotics, has made many farms to resort to alternative therapies such as probiotics and more effective vaccines. Furthermore, the growing rates of poultry production amongst developing countries increases the demand for efficacious medicine/pharmaceuticals, which contributes to the sustainable, safe and productive poultry keeping.
発展途上国からの家禽およびその製品の消費量の増加は、養鶏慣行の増加をもたらし、家禽用薬/医薬品市場の成長の主な原因となっています。家禽の病気、特にニューカッスル病やコクシジウム症の増加により、ワクチン、抗生物質、免疫増強剤の必要性が生じています。また、食品の安全性と抗生物質の削減に対する関心の高まりにより、多くの農場がプロバイオティクスやより効果的なワクチンなどの代替療法に頼るようになっています。さらに、発展途上国における家禽の生産率の上昇により、効果的な医薬品の需要が増加しており、これが持続可能で安全かつ生産的な家禽の飼育に貢献しています。
“By animal type, chickens segment is expected to have the largest market share in the poultry medicine/pharmaceuticals market.”
Based on animal type, the chickens segment is expected to hold the largest market share in the poultry medicine/pharmaceuticals market. Owing to high domestic poultry consumption of protein sources like chicken meat and eggs. This increase in demand has contributed change in age to the poultry farming especially in developing areas with an increase in the production of chickens. Chickens are also commonly affected by several diseases; Newcastle disease, Infectious Bronchitis and Coccidiosis, which explains the use of vaccines, antibiotics and probiotics to enhance the health and productivity of the flocks Several factors attributed to increasing food production also explain the need for higher standards biologically and on farm bio-security interventions. Innovations in vaccine delivery methods such as in ovo vaccination have enhanced the efficiency and effectiveness of immunization on a large scale providing more avenues for consumption of poultry medicine/pharmaceuticals.
“By product, vaccine segment is expected to have the largest market share in the poultry medicine/pharmaceuticals market.”
Based on product, the largest share of this market is vaccines since they are critical in the prevention of infectious diseases which can rapidly spread through large flocks, like Newcastle disease, Infectious Bronchitis, and Avian Influenza. Effective vaccination of a poultry flock ensures health, productivity, and minimization of losses due to eventual flock culling order by the veterinary authority. Regulatory pressure to lower the use of antibiotics makes vaccines a preferred choice in the management of diseases as they prevent infections without adding to antimicrobial resistance. Technology advancement, such as ovo vaccination, allows for efficient mass immunization; thus, vaccine administration has become practical and scalable to large poultry farms. In the context of disease prevention and sustainable farming practices, vaccines have cemented their position as the largest segment in the poultry medicine/pharmaceuticals market.
“By disease indication, newcastle disease segment is expected to have the largest market share in the poultry medicine/pharmaceuticals market.”
Based on disease indication, the largest share of this market is newcastle disease since the disease affects the poultry worldwide and severely impacts poultry farmers economically. High mortality rates and losses in productivity due to outbreak required vaccination programmes; therefore, vaccines against Newcastle disease are indispensable in poultry health management. Second-generation recombinant and thermostable vaccines have helped increase the ease of use and thus their usage in countries with intensive poultry farming. The continued emphasis on disease prevention and government containment programs have made Newcastle Disease the largest category in the poultry medicine/pharmaceuticals market.
“By route of administration, oral segment is expected to have the largest market share in the poultry medicine/pharmaceuticals market.”
Based on route of administration, The oral route of administration in poultry medicine/pharmaceuticals is efficient and convenient in the medication of large flocks in comparison to the other routes as it delivers medication through either water or feed, thereby getting an equal amount of dose delivery to all birds without time-consuming and stressful individual birds’ handling. The oral route is most suited for antibiotics, vaccines, probiotics, and vitamins and therefore used in a very diversified preventive and therapeutic mode of application. Labor cost-cutting, simplification in dosing, and accommodation in large-scale poultry systems where quick effective management of disease is important make this route highly acceptable. Given the practicality and economies of scale involved in oral delivery, this mode forms the mainstay in the poultry farming business and commands the market for medicine/pharmaceuticals.
“By region, North America region is expected to have the largest market share in the poultry medicine/pharmaceuticals market.”
The poultry medicine/pharmaceuticals market is dominated by North America as a result of advanced poultry farming systems prevalent in the region, high poultry products intake, and greater concern for biosecurity and disease control. The region is characterized by existing legislation that encourages responsible antibiotic use and as a consequence drive producers to vaccines and other health solutions in the production of food. Continuous investments in research and development as well as modern technologies put in place for the management and therapy of diseases further promotes upward movement of this market. On top of that, due to the fact that there is a growing need for sustainable as well as high-yield systems of poultry rearing, the production of medicines that assist in maintaining flocks health and productivity has increased in the region thereby further entrenching North America’s market leader position.
A breakdown of the primary participants (supply-side) for the poultry medicine/pharmaceuticals market referred to for this report is provided below:
- By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3–25%
- By Designation: C-level–20%, Director Level–35%, and Others–45%
- By Region: North America–27%, Europe–25%, Asia Pacific–30%, ROW-18%
Prominent players in the poultry medicine/pharmaceuticals market are are MSD (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva Sante Animale (France), Zoetis Service LLC (US), Virbac (France), Phibro Animal Health (US), Hester Biosciences Limited (India), Meiji Animal Health (Japan), Venky’s India (India), Bimeda Corporate (Ireland), Calier (Spain), Hipra (Spain), Vetanco (Argentina), Vaxxinova (Netherlands), Biovac Group (Israel), Kemin Industries (US), O.L.KAR Agrozoovet Service (Ukraine), Indovax (India), Avimex (Mexico), Synthese Elevage (France), Provet Pharma Pvt Ltd (India), Huvepharma (Bulgaria), Romvac Company (Romania), and VMN Pharmaceuticals (Turkey).
Research Coverage:
The report analyzes the poultry medicine/pharmaceuticals market and aims at estimating the market size and future growth potential of this market based on various segments such as animal type, product, route of administration and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall poultry medicine/pharmaceuticals market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
- Analysis of key drivers (increasing poultry consumption, growing incidence of poultry diseases, advances in poultry medicine/pharmaceuticals, initiatives by government agencies and animal associations), restraints (high cost of vaccines development, antibiotic resistance concerns), opportunities (growth in emerging markets, industrialization of poultry farming), challenges (regulatory compliance)
- ZMarket Penetration: It includes extensive information on products offered by the major players in the global the poultry medicine/pharmaceuticals market. The report includes various segments in offering, application, end user and region.
- Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global poultry medicine/pharmaceuticals market.
- Market Development: Thorough knowledge and analysis of the profitable rising markets by offering, application, end user and region.
- Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global the poultry medicine/pharmaceuticals market.
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global poultry medicine/pharmaceuticals market.
Table of Contents
1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.3 MARKETS & REGIONS COVERED 36
1.3.1 YEARS CONSIDERED 37
1.3.2 CURRENCY CONSIDERED 37
1.4 STAKEHOLDERS 38
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.1.1 SECONDARY DATA 40
2.1.1.1 Key data from secondary sources 41
2.1.2 PRIMARY DATA 41
2.1.2.1 Key data from primary sources 42
2.1.2.2 Key industry insights 43
2.2 MARKET SIZE ESTIMATION 45
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 50
2.4 MARKET SHARE ESTIMATION 52
2.5 STUDY ASSUMPTIONS 52
2.6 LIMITATIONS 52
2.6.1 METHODOLOGY-RELATED LIMITATIONS 52
2.6.2 SCOPE-RELATED LIMITATIONS 52
2.7 RISK ASSESSMENT 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 58
4.1 POULTRY PHARMACEUTICALS MARKET OVERVIEW 58
4.2 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET,
BY PRODUCT AND COUNTRY (2023) 59
4.3 POULTRY PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
4.4 POULTRY PHARMACEUTICALS MARKET, BY REGION (2022−2029) 60
4.5 POULTRY PHARMACEUTICALS MARKET: DEVELOPED VS. EMERGING MARKETS 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
5.2.1 DRIVERS 63
5.2.1.1 Increasing poultry consumption 63
5.2.1.2 Growing incidence of poultry diseases 63
5.2.1.3 Advancements in poultry pharmaceuticals 64
5.2.1.4 Favorable initiatives by government agencies & animal
welfare associations 64
5.2.2 RESTRAINTS 65
5.2.2.1 High cost of vaccine development 65
5.2.2.2 Concerns associated with antibiotic resistance 65
5.2.3 OPPORTUNITIES 65
5.2.3.1 High growth potential of emerging economies 65
5.2.3.2 Industrialization of poultry farming 66
5.2.4 CHALLENGES 66
5.2.4.1 Stringent regulatory compliance for poultry pharmaceuticals 66
5.3 INDUSTRY TRENDS 67
5.3.1 ANTIBIOTIC-FREE SOLUTIONS 67
5.3.2 EMERGENCE OF INNOVATIVE VACCINE TECHNOLOGIES 67
5.4 VALUE CHAIN ANALYSIS 67
5.5 SUPPLY CHAIN ANALYSIS 68
5.6 TECHNOLOGY ANALYSIS 70
5.6.1 KEY TECHNOLOGIES 70
5.6.1.1 mRNA vaccines 70
5.6.1.2 Nanoparticle drug delivery 70
5.6.1.3 CRISPR gene editing 70
5.6.2 COMPLEMENTARY TECHNOLOGIES 71
5.6.2.1 IoT-enabled health monitoring 71
5.6.3 ADJACENT TECHNOLOGIES 71
5.6.3.1 Automated drug delivery systems 71
5.7 PORTER’S FIVE FORCES ANALYSIS 72
5.7.1 THREAT OF NEW ENTRANTS 73
5.7.2 THREAT OF SUBSTITUTES 73
5.7.3 BARGAINING POWER OF SUPPLIERS 73
5.7.4 BARGAINING POWER OF BUYERS 73
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 73
5.8 REGULATORY LANDSCAPE 74
5.8.1 REGULATORY ANALYSIS 74
5.8.1.1 US 74
5.8.1.2 Europe 74
5.8.1.3 Asia Pacific 74
5.8.1.4 Latin America 74
5.8.1.5 Middle East & Africa 75
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 75
5.8.2.1 North America 75
5.8.2.2 Europe 76
5.8.2.3 Rest of the World 77
5.9 PATENT ANALYSIS 78
5.9.1 PATENT PUBLICATION TRENDS FOR POULTRY PHARMACEUTICALS 78
5.10 TRADE ANALYSIS 81
5.11 PRICING ANALYSIS 83
5.11.1 AVERAGE SELLING PRICE TREND OF POULTRY PHARMACEUTICALS, BY REGION (2022−2024) 83
5.11.2 AVERAGE SELLING PRICE OF POULTRY VACCINES, BY KEY PLAYER (2023) 84
5.12 KEY CONFERENCES AND EVENTS, 2024−2025 84
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 85
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 85
5.13.2 BUYING CRITERIA 85
5.14 UNMET NEEDS AND END-USER EXPECTATIONS 86
5.14.1 UNMET NEEDS 86
5.14.2 END-USER EXPECTATIONS 88
5.15 ECOSYSTEM MARKET ANALYSIS 88
5.16 CASE STUDY ANALYSIS 90
5.16.1 CASE STUDY 1: MARKET DEVELOPMENT IN NIGER DELTA (MADE) 90
5.16.2 CASE STUDY 2: JOURNEY OF TRIBAL WOMEN 91
5.16.3 CASE STUDY 3: PROBLEMS & PROSPECTS OF POULTRY FARMING IN CHITTOOR, ANDHRA PRADESH 91
5.17 ADJACENT MARKET ANALYSIS 92
5.18 INVESTMENT & FUNDING SCENARIO 92
5.19 IMPACT OF AI/GENAI ON POULTRY PHARMACEUTICALS MARKET 93
6 POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE 94
6.1 INTRODUCTION 95
6.2 CHICKEN 96
6.2.1 BROILER 99
6.2.1.1 Specifically bred for high meat yield to drive market 99
6.2.2 LAYER 102
6.2.2.1 Growing demand for eggs to fuel market 102
6.3 TURKEY 105
6.3.1 CONSUMER PREFERENCE FOR ORGANIC TURKEY BY-PRODUCTS TO
DRIVE MARKET 105
6.4 DUCK 108
6.4.1 GROWING FOCUS ON DEVELOPMENT OF TARGETED VACCINES FOR
DVH TO FUEL UPTAKE 108
6.5 OTHER POULTRY 110
7 POULTRY PHARMACEUTICALS MARKET, BY PRODUCT 113
7.1 INTRODUCTION 114
7.2 DRUGS 115
7.2.1 ANTIBIOTICS 118
7.2.1.1 Most widely used drug in poultry management to drive market 118
7.2.2 ANTIPARASITICS 121
7.2.2.1 Ability to combat against coccidiosis and ectoparasites to
boost demand 121
7.2.3 ANTISEPTICS 124
7.2.3.1 Maintainance of biosecurity through infection reduction to
fuel uptake 124
7.2.4 NUTRITIONALS 127
7.2.4.1 Optimization of poultry health with enhanced productivity to
support market growth 127
7.2.5 OTHER DRUGS 130
7.3 VACCINES 132
7.3.1 LIVE-ATTENUATED VACCINES 136
7.3.1.1 Cost-efficiency and high efficacy benefits to fuel uptake 136
7.3.2 INACTIVATED VACCINES 139
7.3.2.1 Pathogen carriers with high stability to drive market 139
7.3.3 RECOMBINANT VACCINES 142
7.3.3.1 Ability to combat several avian diseases to boost demand 142
7.3.4 OTHER VACCINES 144
7.4 FEED ADDITIVES 147
7.4.1 ADDITIONAL INCORPORATION TO DIETS FOR ENHANCED BENEFITS
TO SUPPORT MARKET GROWTH 147
8 POULTRY PHARMACEUTICALS MARKET, BY DISEASE TYPE 150
8.1 INTRODUCTION 151
8.2 NEWCASTLE DISEASE 152
8.2.1 INNOVATIONS IN NEXT-GEN VACCINES TO PROPEL MARKET 152
8.3 INFECTIOUS BRONCHITIS 155
8.3.1 HIGH MORTALITY CASES TO BOOST DEMAND 155
8.4 INFECTIOUS BURSAL DISEASE 158
8.4.1 GROWING DEMAND FOR MULTIVALENT VACCINES TO FUEL MARKET 158
8.5 COCCIDIOSIS 161
8.5.1 DEVELOPMENT OF ANTI-COCCIDIAL DRUGS TO FUEL UPTAKE 161
8.6 SALMONELLA 164
8.6.1 INCREASING INCIDENCE OF SALMONELLA OUTBREAKS TO DRIVE MARKET 164
8.7 MAREK’S DISEASE 167
8.7.1 GROWING FOCUS ON ENSURING FLOCK PRODUCTIVITY TO SUPPORT MARKET 167
8.8 OTHER DISEASES 169
9 POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION 172
9.1 INTRODUCTION 173
9.2 ORAL ROUTE OF ADMINISTRATION 174
9.2.1 HIGH UPTAKE OF ANTIBIOTICS DUE TO SCALABILITY AND COST-EFFICIENCY TO DRIVE MARKET 174
9.3 INJECTABLE ROUTE OF ADMINISTRATION 177
9.3.1 RAPID TREATMENT RESPONSE TO FUEL MARKET 177
9.4 TOPICAL ROUTE OF ADMINISTRATION 180
9.4.1 UPTAKE OF ANTIPARASITIC TREATMENT TO SUPPORT MARKET GROWTH 180
9.5 OTHER ROUTES 182
10 POULTRY PHARMACEUTICALS MARKET, BY REGION 185
10.1 INTRODUCTION 186
10.2 NORTH AMERICA 187
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 194
10.2.2 US 194
10.2.2.1 Stringent regulatory protocols for disease prevention to drive market 194
10.2.3 CANADA 200
10.2.3.1 Growing focus on animal health to drive market 200
10.3 EUROPE 205
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 211
10.3.2 GERMANY 212
10.3.2.1 Growing awareness of poultry health issues in Germany 212
10.3.3 UK 218
10.3.3.1 Growing focus on antibiotic-free poultry to boost demand 218
10.3.4 FRANCE 223
10.3.4.1 Avian influenza outbreaks and disease prevention strategies to
fuel market growth 223
10.3.5 SPAIN 228
10.3.5.1 Increased poultry production and export to drive market 228
10.3.6 ITALY 234
10.3.6.1 Rising poultry trade and biosecurity measures to drive market 234
10.3.7 REST OF EUROPE 240
10.4 ASIA PACIFIC 245
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 252
10.4.2 JAPAN 253
10.4.2.1 Focus on biosecurity and innovative pharmaceutical products to drive market 253
10.4.3 CHINA 259
10.4.3.1 Increasing incidence of avian influenza to boost demand 259
10.4.4 INDIA 264
10.4.4.1 Rapid expansion of poultry farming to fuel uptake 264
10.4.5 AUSTRALIA 270
10.4.5.1 Growing focus on advanced pharmaceuticals to support market 270
10.4.6 SOUTH KOREA 275
10.4.6.1 Frequent outbreak of coccidiosis to support market growth 275
10.4.7 REST OF ASIA PACIFIC 281
10.5 LATIN AMERICA 286
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 292
10.5.2 BRAZIL 293
10.5.2.1 Surge in poultry export to fuel uptake 293
10.5.3 MEXICO 299
10.5.3.1 Increasing investments in broiler genetics to propel market 299
10.5.4 REST OF LATIN AMERICA 304
10.6 MIDDLE EAST & AFRICA 310
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 315
10.6.2 GCC COUNTRIES 316
10.6.2.1 Expanding poultry sector to fuel uptake 316
10.6.3 REST OF MIDDLE EAST & AFRICA 322
11 COMPETITIVE LANDSCAPE 328
11.1 OVERVIEW 328
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 328
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POULTRY PHARMACEUTICALS MARKET 329
11.3 REVENUE ANALYSIS, 2019−2023 330
11.4 MARKET SHARE ANALYSIS, 2023 331
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 333
11.5.1 STARS 333
11.5.2 EMERGING LEADERS 334
11.5.3 PERVASIVE PLAYERS 334
11.5.4 PARTICIPANTS 334
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 336
11.5.5.1 Company footprint 336
11.5.5.2 Region footprint 337
11.5.5.3 Animal type footprint 338
11.5.5.4 Product footprint 339
11.5.5.5 Disease indication footprint 340
11.5.5.6 Route of administration footprint 341
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 342
11.6.1 PROGRESSIVE COMPANIES 342
11.6.2 RESPONSIVE COMPANIES 342
11.6.3 DYNAMIC COMPANIES 342
11.6.4 STARTING BLOCKS 342
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 344
11.7 COMPANY VALUATION & FINANCIAL METRICS 345
11.7.1 FINANCIAL METRICS 345
11.7.2 COMPANY VALUATION 345
11.8 BRAND/PRODUCT COMPARISON 346
11.9 COMPETITIVE SCENARIO 346
11.9.1 PRODUCT LAUNCHES & APPROVALS 346
11.9.2 DEALS 347
11.9.3 EXPANSIONS 348
11.9.4 OTHER DEVELOPMENTS 348
12 COMPANY PROFILES 349
12.1 KEY PLAYERS 349
12.1.1 MERCK ANIMAL HEALTH (SUBSIDIARY OF MERCK & CO., INC.) 349
12.1.1.1 Business overview 349
12.1.1.2 Products offered 350
12.1.1.3 MnM view 352
12.1.1.3.1 Key strengths 352
12.1.1.3.2 Strategic choices 352
12.1.1.3.3 Weaknesses & competitive threats 352
12.1.2 ELANCO 353
12.1.2.1 Business overview 353
12.1.2.2 Products offered 354
12.1.2.3 Recent developments 355
12.1.2.3.1 Deals 355
12.1.2.3.2 Expansions 356
12.1.2.4 MnM view 356
12.1.2.4.1 Key strengths 356
12.1.2.4.2 Strategic choices 356
12.1.2.4.3 Weaknesses & competitive threats 356
12.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 357
12.1.3.1 Business overview 357
12.1.3.2 Products offered 358
12.1.3.3 Recent developments 359
12.1.3.3.1 Product approvals 359
12.1.3.3.2 Deals 359
12.1.3.3.3 Expansions 360
12.1.3.4 MnM view 360
12.1.3.4.1 Key strengths 360
12.1.3.4.2 Strategic choices 360
12.1.3.4.3 Weaknesses & competitive threats 360
12.1.4 CEVA SANTÉ ANIMALE 361
12.1.4.1 Business overview 361
12.1.4.2 Products offered 361
12.1.4.3 MnM view 362
12.1.4.3.1 Key strengths 362
12.1.4.3.2 Strategic choices 362
12.1.4.3.3 Weaknesses & competitive threats 362
12.1.5 ZOETIS SERVICES LLC 363
12.1.5.1 Business overview 363
12.1.5.2 Products offered 364
12.1.5.3 Recent developments 366
12.1.5.3.1 Deals 366
12.1.5.3.2 Expansions 366
12.1.5.3.3 Other developments 366
12.1.5.4 MnM view 367
12.1.5.4.1 Key strengths 367
12.1.5.4.2 Strategic choices 367
12.1.5.4.3 Weaknesses & competitive threats 367
12.1.6 VIRBAC 368
12.1.6.1 Business overview 368
12.1.6.2 Products offered 369
12.1.6.3 Recent developments 370
12.1.6.3.1 Deals 370
12.1.7 PHIBRO ANIMAL HEALTH CORPORATION 371
12.1.7.1 Business overview 371
12.1.7.2 Products offered 372
12.1.7.3 Recent developments 374
12.1.7.3.1 Deals 374
12.1.8 HESTER BIOSCIENCES LIMITED 375
12.1.8.1 Business overview 375
12.1.8.2 Products offered 376
12.1.8.3 Recent developments 378
12.1.8.3.1 Deals 378
12.1.9 MEIJI ANIMAL HEALTH CO, LTD. (SUBSIDIARY OF K.M BIOLOGICS CO. LTD.) 379
12.1.9.1 Business overview 379
12.1.9.2 Products offered 380
12.1.10 VENKY’S INDIA 382
12.1.10.1 Business overview 382
12.1.10.2 Products offered 383
12.1.11 BIMEDA CORPORATE 386
12.1.11.1 Business overview 386
12.1.11.2 Products offered 386
12.1.12 CALIER 388
12.1.12.1 Business overview 388
12.1.12.2 Products offered 388
12.1.13 HIPRA 390
12.1.13.1 Business overview 390
12.1.13.2 Products offered 391
12.1.14 VETANCO 392
12.1.14.1 Business overview 392
12.1.14.2 Products offered 392
12.1.15 VAXXINOVA INTERNATIONAL BV 394
12.1.15.1 Business overview 394
12.1.15.2 Products offered 394
12.1.16 BIOVAC GROUP 396
12.1.16.1 Business overview 396
12.1.16.2 Products offered 396
12.1.17 KEMIN INDUSTRIES, INC. 399
12.1.17.1 Business overview 399
12.1.17.2 Products offered 399
12.1.18 О.L.KAR.-AGROZOOVET-SERVICE 401
12.1.18.1 Business overview 401
12.1.18.2 Products offered 401
12.1.19 INDOVAX 404
12.1.19.1 Business overview 404
12.1.19.2 Products offered 405
12.1.20 AVIMEX 406
12.1.20.1 Business overview 406
12.1.20.2 Products offered 406
12.2 OTHER PLAYERS 408
12.2.1 SYNTHÈSE ÉLEVAGE 408
12.2.2 PROVET PHARMA PRIVATE LIMITED 410
12.2.3 HUVEPHARMA 412
12.2.4 ROMVAC COMPANY S.A. 413
12.2.5 VMN PHARMACEUTICALS 414
13 APPENDIX 417
13.1 DISCUSSION GUIDE 417
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 421
13.3 CUSTOMIZATION OPTIONS 423
13.4 RELATED REPORTS 423
13.5 AUTHOR DETAILS 424
LIST OF TABLES
TABLE 1 STANDARD CURRENCY CONVERSION RATES 37
TABLE 2 POULTRY PHARMACEUTICALS MARKET: RISK ASSESSMENT ANALYSIS 53
TABLE 3 IMPACT ANALYSIS OF PORTER’S FIVE FORCES 72
TABLE 4 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 75
TABLE 5 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 76
TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 7 LIST OF PATENTS IN POULTRY PHARMACEUTICALS MARKET, 2022–2024 79
TABLE 8 IMPORT DATA FOR MEDICAMENTS CONSISTING OF MIXED OR UNMIXED PRODUCTS FOR THERAPEUTIC OR PROPHYLACTIC PURPOSES (HS CODE 300490), BY COUNTRY, 2019–2023 (USD THOUSAND) 81
TABLE 9 EXPORT DATA FOR MEDICAMENTS CONSISTING OF MIXED OR UNMIXED PRODUCTS FOR THERAPEUTIC OR PROPHYLACTIC PURPOSES (HS CODE 300490), BY COUNTRY, 2019–2023 (USD THOUSAND) 82
TABLE 10 AVERAGE SELLING PRICE TREND OF POULTRY PHARMACEUTICAL PRODUCTS,
BY REGION (2022−2024) 83
TABLE 11 AVERAGE SELLING PRICE OF POULTRY VACCINES, BY KEY PLAYER (2023) (USD) 84
TABLE 12 POULTRY PHARMACEUTICALS MARKET: KEY CONFERENCES & EVENTS,
2024-2025 84
TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DRUGS,
VACCINES, AND FEED ADDITIVES 85
TABLE 14 KEY BUYING CRITERIA FOR DRUGS, VACCINES, AND FEED ADDITIVES 86
TABLE 15 END-USER EXPECTATIONS FOR DRUGS, VACCINES, AND FEED ADDITIVES 88
TABLE 16 POULTRY PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS 89
TABLE 17 POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 95
TABLE 18 POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 95
TABLE 19 CHICKEN PHARMACEUTICALS MARKET, BY TYPE, 2019–2022 (USD MILLION) 96
TABLE 20 CHICKEN PHARMACEUTICALS MARKET, BY TYPE, 2023–2029 (USD MILLION) 96
TABLE 21 CHICKEN PHARMACEUTICALS MARKET, BY REGION, 2019–2022 (USD MILLION) 97
TABLE 22 CHICKEN PHARMACEUTICALS MARKET, BY REGION, 2023–2029 (USD MILLION) 98
TABLE 23 BROILER PHARMACEUTICALS MARKET, BY REGION, 2019–2022 (USD MILLION) 100
TABLE 24 BROILER PHARMACEUTICALS MARKET, BY REGION, 2023–2029 (USD MILLION) 101
TABLE 25 LAYER PHARMACEUTICALS MARKET, BY REGION, 2019–2022 (USD MILLION) 103
TABLE 26 LAYER PHARMACEUTICALS MARKET, BY REGION, 2023–2029 (USD MILLION) 104
TABLE 27 TURKEY PHARMACEUTICALS MARKET, BY REGION, 2019–2022 (USD MILLION) 106
TABLE 28 TURKEY PHARMACEUTICALS MARKET, BY REGION, 2023–2029 (USD MILLION) 107
TABLE 29 DUCK PHARMACEUTICALS MARKET, BY REGION, 2019–2022 (USD MILLION) 109
TABLE 30 DUCK PHARMACEUTICALS MARKET, BY REGION, 2023–2029 (USD MILLION) 110
TABLE 31 OTHER POULTRY PHARMACEUTICALS MARKET, BY REGION,
2019–2022 (USD MILLION) 111
TABLE 32 OTHER POULTRY PHARMACEUTICALS MARKET, BY REGION,
2023–2029 (USD MILLION) 112
TABLE 33 POULTRY PHARMACEUTICALS MARKET, BY PRODUCT, 2019–2022 (USD MILLION) 114
TABLE 34 POULTRY PHARMACEUTICALS MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 114
TABLE 35 POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 115
TABLE 36 POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 115
TABLE 37 POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY REGION,
2019–2022 (USD MILLION) 116
TABLE 38 POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY REGION,
2023–2029 (USD MILLION) 117
TABLE 39 POULTRY PHARMACEUTICALS MARKET FOR ANTIBIOTICS, BY REGION,
2019–2022 (USD MILLION) 119
TABLE 40 POULTRY PHARMACEUTICALS MARKET FOR ANTIBIOTICS, BY REGION,
2023–2029 (USD MILLION) 120
TABLE 41 POULTRY PHARMACEUTICALS MARKET FOR ANTIPARASITICS, BY REGION,
2019–2022 (USD MILLION) 122
TABLE 42 POULTRY PHARMACEUTICALS MARKET FOR ANTIPARASITICS, BY REGION,
2023–2029 (USD MILLION) 123
TABLE 43 POULTRY PHARMACEUTICALS MARKET FOR ANTISEPTICS, BY REGION,
2019–2022 (USD MILLION) 125
TABLE 44 POULTRY PHARMACEUTICALS MARKET FOR ANTISEPTICS, BY REGION,
2023–2029 (USD MILLION) 126
TABLE 45 POULTRY PHARMACEUTICALS MARKET FOR NUTRITIONALS, BY REGION,
2019–2022 (USD MILLION) 128
TABLE 46 POULTRY PHARMACEUTICALS MARKET FOR NUTRITIONALS, BY REGION,
2023–2029 (USD MILLION) 129
TABLE 47 POULTRY PHARMACEUTICALS MARKET FOR OTHER DRUGS, BY REGION,
2019–2022 (USD MILLION) 131
TABLE 48 POULTRY PHARMACEUTICALS MARKET FOR OTHER DRUGS, BY REGION,
2023–2029 (USD MILLION) 132
TABLE 49 POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 133
TABLE 50 POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 133
TABLE 51 POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY REGION,
2019–2022 (USD MILLION) 134
TABLE 52 POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY REGION,
2023–2029 (USD MILLION) 135
TABLE 53 POULTRY PHARMACEUTICALS MARKET FOR LIVE-ATTENUATED VACCINES,
BY REGION, 2019–2022 (USD MILLION) 137
TABLE 54 POULTRY PHARMACEUTICALS MARKET FOR LIVE-ATTENUATED VACCINES,
BY REGION, 2023–2029 (USD MILLION) 138
TABLE 55 POULTRY PHARMACEUTICALS MARKET FOR INACTIVATED VACCINES, BY REGION, 2019–2022 (USD MILLION) 140
TABLE 56 POULTRY PHARMACEUTICALS MARKET FOR INACTIVATED VACCINES, BY REGION, 2023–2029 (USD MILLION) 141
TABLE 57 POULTRY PHARMACEUTICALS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2019–2022 (USD MILLION) 143
TABLE 58 POULTRY PHARMACEUTICALS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2023–2029 (USD MILLION) 144
TABLE 59 POULTRY PHARMACEUTICALS MARKET FOR OTHER VACCINES, BY REGION,
2019–2022 (USD MILLION) 145
TABLE 60 POULTRY PHARMACEUTICALS MARKET FOR OTHER VACCINES, BY REGION,
2023–2029 (USD MILLION) 146
TABLE 61 POULTRY PHARMACEUTICALS MARKET FOR FEED ADDITIVES, BY REGION,
2019–2022 (USD MILLION) 148
TABLE 62 POULTRY PHARMACEUTICALS MARKET FOR FEED ADDITIVES, BY REGION,
2023–2029 (USD MILLION) 149
TABLE 63 POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 151
TABLE 64 POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 151
TABLE 65 POULTRY PHARMACEUTICALS MARKET FOR NEWCASTLE DISEASE, BY REGION, 2019–2022 (USD MILLION) 153
TABLE 66 POULTRY PHARMACEUTICALS MARKET FOR NEWCASTLE DISEASE, BY REGION, 2023–2029 (USD MILLION) 154
TABLE 67 POULTRY PHARMACEUTICALS MARKET FOR INFECTIOUS BRONCHITIS, BY REGION, 2019–2022 (USD MILLION) 156
TABLE 68 POULTRY PHARMACEUTICALS MARKET FOR INFECTIOUS BRONCHITIS, BY REGION, 2023–2029 (USD MILLION) 157
TABLE 69 POULTRY PHARMACEUTICALS MARKET FOR INFECTIOUS BURSAL DISEASE,
BY REGION, 2019–2022 (USD MILLION) 159
TABLE 70 POULTRY PHARMACEUTICALS MARKET FOR INFECTIOUS BURSAL DISEASE,
BY REGION, 2023–2029 (USD MILLION) 160
TABLE 71 POULTRY PHARMACEUTICALS MARKET FOR COCCIDIOSIS, BY REGION,
2019–2022 (USD MILLION) 162
TABLE 72 POULTRY PHARMACEUTICALS MARKET FOR COCCIDIOSIS, BY REGION,
2023–2029 (USD MILLION) 163
TABLE 73 POULTRY PHARMACEUTICALS MARKET FOR SALMONELLA, BY REGION,
2019–2022 (USD MILLION) 165
TABLE 74 POULTRY PHARMACEUTICALS MARKET FOR SALMONELLA, BY REGION,
2023–2029 (USD MILLION) 166
TABLE 75 POULTRY PHARMACEUTICALS MARKET FOR MAREK’S DISEASE, BY REGION, 2019–2022 (USD MILLION) 168
TABLE 76 POULTRY PHARMACEUTICALS MARKET FOR MAREK’S DISEASE, BY REGION, 2023–2029 (USD MILLION) 169
TABLE 77 POULTRY PHARMACEUTICALS MARKET FOR OTHER DISEASES, BY REGION,
2019–2022 (USD MILLION) 170
TABLE 78 POULTRY PHARMACEUTICALS MARKET FOR OTHER DISEASES, BY REGION,
2023–2029 (USD MILLION) 171
TABLE 79 POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION,
2019–2022 (USD MILLION) 173
TABLE 80 POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2029 (USD MILLION) 173
TABLE 81 ORAL ROUTE OF ADMINISTRATION MARKET, BY REGION,
2019–2022 (USD MILLION) 175
TABLE 82 ORAL ROUTE OF ADMINISTRATION MARKET, BY REGION,
2023–2029 (USD MILLION) 176
TABLE 83 INJECTABLE ROUTE OF ADMINISTRATION MARKET, BY REGION,
2019–2022 (USD MILLION) 178
TABLE 84 INJECTABLE ROUTE OF ADMINISTRATION MARKET, BY REGION,
2023–2029 (USD MILLION) 179
TABLE 85 TOPICAL ROUTE OF ADMINISTRATION MARKET, BY REGION,
2019–2022 (USD MILLION) 181
TABLE 86 TOPICAL ROUTE OF ADMINISTRATION MARKET, BY REGION,
2023–2029 (USD MILLION) 182
TABLE 87 OTHER ROUTES OF ADMINISTRATION MARKET, BY REGION,
2019–2022 (USD MILLION) 183
TABLE 88 OTHER ROUTES OF ADMINISTRATION MARKET, BY REGION,
2023–2029 (USD MILLION) 184
TABLE 89 POULTRY PHARMACEUTICALS MARKET, BY REGION, 2019–2022 (USD MILLION) 187
TABLE 90 POULTRY PHARMACEUTICALS MARKET, BY REGION, 2023–2029 (USD MILLION) 187
TABLE 91 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET, BY COUNTRY,
2019–2022 (USD MILLION) 188
TABLE 92 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET, BY COUNTRY,
2023–2029 (USD MILLION) 189
TABLE 93 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 189
TABLE 94 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 189
TABLE 95 NORTH AMERICA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 190
TABLE 96 NORTH AMERICA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 190
TABLE 97 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 190
TABLE 98 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 191
TABLE 99 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2019–2022 (USD MILLION) 191
TABLE 100 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2023–2029 (USD MILLION) 191
TABLE 101 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 192
TABLE 102 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 192
TABLE 103 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2019–2022 (USD MILLION) 192
TABLE 104 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2023–2029 (USD MILLION) 193
TABLE 105 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 193
TABLE 106 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 193
TABLE 107 US: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 195
TABLE 108 US: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 195
TABLE 109 US: POULTRY PHARMACEUTICALS MARKET FOR CHICKEN, BY TYPE,
2019–2022 (USD MILLION) 196
TABLE 110 US: POULTRY PHARMACEUTICALS MARKET FOR CHICKEN, BY TYPE,
2023–2029 (USD MILLION) 196
TABLE 111 US: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 196
TABLE 112 US: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 197
TABLE 113 US: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE
2019–2022 (USD MILLION) 197
TABLE 114 US: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE
2023–2029 (USD MILLION) 197
TABLE 115 US: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 198
TABLE 116 US: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 198
TABLE 117 US: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 198
TABLE 118 US: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 199
TABLE 119 US: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 199
TABLE 120 US: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 199
TABLE 121 CANADA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 200
TABLE 122 CANADA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 201
TABLE 123 CANADA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 201
TABLE 124 CANADA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 201
TABLE 125 CANADA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 202
TABLE 126 CANADA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 202
TABLE 127 CANADA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 202
TABLE 128 CANADA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 203
TABLE 129 CANADA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 203
TABLE 130 CANADA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 203
TABLE 131 CANADA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 204
TABLE 132 CANADA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 204
TABLE 133 CANADA: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 205
TABLE 134 CANADA: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 205
TABLE 135 EUROPE: POULTRY PHARMACEUTICALS MARKET, BY COUNTRY,
2019–2022 (USD MILLION) 206
TABLE 136 EUROPE: POULTRY PHARMACEUTICALS MARKET, BY COUNTRY,
2023–2029 (USD MILLION) 206
TABLE 137 EUROPE: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 206
TABLE 138 EUROPE: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 207
TABLE 139 EUROPE: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 207
TABLE 140 EUROPE: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 207
TABLE 141 EUROPE: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 208
TABLE 142 EUROPE: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 208
TABLE 143 EUROPE: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 208
TABLE 144 EUROPE: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 209
TABLE 145 EUROPE: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 209
TABLE 146 EUROPE: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 209
TABLE 147 EUROPE: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 210
TABLE 148 EUROPE: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 210
TABLE 149 EUROPE: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 211
TABLE 150 EUROPE: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 211
TABLE 151 GERMANY: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 213
TABLE 152 GERMANY: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 213
TABLE 153 GERMANY: POULTRY PHARMACEUTICALS MARKET FOR CHICKEN, BY TYPE,
2019–2022 (USD MILLION) 213
TABLE 154 GERMANY: POULTRY PHARMACEUTICALS MARKET FOR CHICKEN, BY TYPE,
2023–2029 (USD MILLION) 214
TABLE 155 GERMANY: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 214
TABLE 156 GERMANY: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 214
TABLE 157 GERMANY: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE
2019–2022 (USD MILLION) 215
TABLE 158 GERMANY: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE
2023–2029 (USD MILLION) 215
TABLE 159 GERMANY: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 215
TABLE 160 GERMANY: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 216
TABLE 161 GERMANY: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2019–2022 (USD MILLION) 216
TABLE 162 GERMANY: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2023–2029 (USD MILLION) 217
TABLE 163 GERMANY: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 217
TABLE 164 GERMANY: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 217
TABLE 165 UK: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 218
TABLE 166 UK: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 218
TABLE 167 UK: CHICKEN PHARMACEUTICALS MARKET, BY TYPE, 2019–2022 (USD MILLION) 219
TABLE 168 UK: CHICKEN PHARMACEUTICALS MARKET, BY TYPE, 2023–2029 (USD MILLION) 219
TABLE 169 UK: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 219
TABLE 170 UK: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 219
TABLE 171 UK: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 220
TABLE 172 UK: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 220
TABLE 173 UK: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 220
TABLE 174 UK: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 221
TABLE 175 UK: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 221
TABLE 176 UK: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 222
TABLE 177 UK: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 222
TABLE 178 UK: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 222
TABLE 179 FRANCE: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 223
TABLE 180 FRANCE: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 224
TABLE 181 FRANCE: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 224
TABLE 182 FRANCE: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 224
TABLE 183 FRANCE: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 225
TABLE 184 FRANCE: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 225
TABLE 185 FRANCE: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 225
TABLE 186 FRANCE: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 226
TABLE 187 FRANCE: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 226
TABLE 188 FRANCE: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 226
TABLE 189 FRANCE: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 227
TABLE 190 FRANCE: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 227
TABLE 191 FRANCE: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 228
TABLE 192 FRANCE: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 228
TABLE 193 SPAIN: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 229
TABLE 194 SPAIN: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 229
TABLE 195 SPAIN: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 230
TABLE 196 SPAIN: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 230
TABLE 197 SPAIN: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 230
TABLE 198 SPAIN: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 230
TABLE 199 SPAIN: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 231
TABLE 200 SPAIN: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 231
TABLE 201 SPAIN: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 231
TABLE 202 SPAIN: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 232
TABLE 203 SPAIN: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 232
TABLE 204 SPAIN: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 233
TABLE 205 SPAIN: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 233
TABLE 206 SPAIN: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 233
TABLE 207 ITALY: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 235
TABLE 208 ITALY: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 235
TABLE 209 ITALY: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 235
TABLE 210 ITALY: CHICEKN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 236
TABLE 211 ITALY: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 236
TABLE 212 ITALY: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 236
TABLE 213 ITALY: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 237
TABLE 214 ITALY: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 237
TABLE 215 ITALY: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 237
TABLE 216 ITALY: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 238
TABLE 217 ITALY: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 238
TABLE 218 ITALY: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 239
TABLE 219 ITALY: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 239
TABLE 220 ITALY: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 239
TABLE 221 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2022 (USD MILLION) 240
TABLE 222 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2023–2029 (USD MILLION) 241
TABLE 223 REST OF EUROPE: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 241
TABLE 224 REST OF EUROPE: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 241
TABLE 225 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 242
TABLE 226 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 242
TABLE 227 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2019–2022 (USD MILLION) 242
TABLE 228 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2023–2029 (USD MILLION) 243
TABLE 229 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 243
TABLE 230 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 243
TABLE 231 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET,
BY DISEASE INDICATION, 2019–2022 (USD MILLION) 244
TABLE 232 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET,
BY DISEASE INDICATION, 2023–2029 (USD MILLION) 244
TABLE 233 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 245
TABLE 234 REST OF EUROPE: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 245
TABLE 235 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY COUNTRY,
2019–2022 (USD MILLION) 247
TABLE 236 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY COUNTRY,
2023–2029 (USD MILLION) 247
TABLE 237 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 247
TABLE 238 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 248
TABLE 239 ASIA PACIFIC: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 248
TABLE 240 ASIA PACIFIC: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 248
TABLE 241 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 249
TABLE 242 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 249
TABLE 243 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 249
TABLE 244 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 250
TABLE 245 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 250
TABLE 246 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 250
TABLE 247 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2019–2022 (USD MILLION) 251
TABLE 248 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2023–2029 (USD MILLION) 251
TABLE 249 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 252
TABLE 250 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 252
TABLE 251 JAPAN: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 254
TABLE 252 JAPAN: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 254
TABLE 253 JAPAN: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 254
TABLE 254 JAPAN: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 255
TABLE 255 JAPAN: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 255
TABLE 256 JAPAN: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 255
TABLE 257 JAPAN: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 256
TABLE 258 JAPAN: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 256
TABLE 259 JAPAN: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 256
TABLE 260 JAPAN: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 257
TABLE 261 JAPAN: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 257
TABLE 262 JAPAN: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 258
TABLE 263 JAPAN: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 258
TABLE 264 JAPAN: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 258
TABLE 265 CHINA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 259
TABLE 266 CHINA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 260
TABLE 267 CHINA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 260
TABLE 268 CHINA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 260
TABLE 269 CHINA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 261
TABLE 270 CHINA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 261
TABLE 271 CHINA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 261
TABLE 272 CHINA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 262
TABLE 273 CHINA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 262
TABLE 274 CHINA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 262
TABLE 275 CHINA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 263
TABLE 276 CHINA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 263
TABLE 277 CHINA: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 264
TABLE 278 CHINA: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 264
TABLE 279 INDIA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 265
TABLE 280 INDIA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 265
TABLE 281 INDIA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 266
TABLE 282 INDIA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 266
TABLE 283 INDIA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 266
TABLE 284 INDIA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 266
TABLE 285 INDIA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 267
TABLE 286 INDIA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2023–2029 (USD MILLION) 267
TABLE 287 INDIA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 267
TABLE 288 INDIA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 268
TABLE 289 INDIA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2019–2022 (USD MILLION) 268
TABLE 290 INDIA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2023–2029 (USD MILLION) 269
TABLE 291 INDIA: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 269
TABLE 292 INDIA: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 269
TABLE 293 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 270
TABLE 294 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 271
TABLE 295 AUSTRALIA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 271
TABLE 296 AUSTRALIA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 271
TABLE 297 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 272
TABLE 298 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 272
TABLE 299 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 272
TABLE 300 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 273
TABLE 301 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 273
TABLE 302 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 273
TABLE 303 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2019–2022 (USD MILLION) 274
TABLE 304 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2023–2029 (USD MILLION) 274
TABLE 305 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 275
TABLE 306 AUSTRALIA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 275
TABLE 307 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 276
TABLE 308 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 276
TABLE 309 SOUTH KOREA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 276
TABLE 310 SOUTH KOREA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 277
TABLE 311 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 277
TABLE 312 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 277
TABLE 313 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2019–2022 (USD MILLION) 278
TABLE 314 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2023–2029 (USD MILLION) 278
TABLE 315 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 278
TABLE 316 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 279
TABLE 317 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2019–2022 (USD MILLION) 279
TABLE 318 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2023–2029 (USD MILLION) 280
TABLE 319 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 280
TABLE 320 SOUTH KOREA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 280
TABLE 321 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2022 (USD MILLION) 281
TABLE 322 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2023–2029 (USD MILLION) 282
TABLE 323 REST OF ASIA PACIFIC: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 282
TABLE 324 REST OF ASIA PACIFIC: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 282
TABLE 325 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET,
BY PRODUCT, 2019–2022 (USD MILLION) 283
TABLE 326 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET,
BY PRODUCT, 2023–2029 (USD MILLION) 283
TABLE 327 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2019–2022 (USD MILLION) 283
TABLE 328 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2023–2029 (USD MILLION) 284
TABLE 329 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET FOR VACCINES,
BY TYPE, 2019–2022 (USD MILLION) 284
TABLE 330 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET FOR VACCINES,
BY TYPE, 2023–2029 (USD MILLION) 284
TABLE 331 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET,
BY DISEASE INDICATION, 2019–2022 (USD MILLION) 285
TABLE 332 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET,
BY DISEASE INDICATION, 2023–2029 (USD MILLION) 285
TABLE 333 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 286
TABLE 334 REST OF ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 286
TABLE 335 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY COUNTRY,
2019–2022 (USD MILLION) 287
TABLE 336 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY COUNTRY,
2023–2029 (USD MILLION) 287
TABLE 337 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 287
TABLE 338 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 288
TABLE 339 LATIN AMERICA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 288
TABLE 340 LATIN AMERICA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 288
TABLE 341 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 289
TABLE 342 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 289
TABLE 343 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2019–2022 (USD MILLION) 289
TABLE 344 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2023–2029 (USD MILLION) 290
TABLE 345 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 290
TABLE 346 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 290
TABLE 347 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2019–2022 (USD MILLION) 291
TABLE 348 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2023–2029 (USD MILLION) 291
TABLE 349 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 292
TABLE 350 LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 292
TABLE 351 BRAZIL: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 294
TABLE 352 BRAZIL: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 294
TABLE 353 BRAZIL: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 294
TABLE 354 BRAZIL: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 295
TABLE 355 BRAZIL: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 295
TABLE 356 BRAZIL: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 295
TABLE 357 BRAZIL: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 296
TABLE 358 BRAZIL: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 296
TABLE 359 BRAZIL: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 296
TABLE 360 BRAZIL: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 297
TABLE 361 BRAZIL: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 297
TABLE 362 BRAZIL: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 298
TABLE 363 BRAZIL: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 298
TABLE 364 BRAZIL: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 298
TABLE 365 MEXICO: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 299
TABLE 366 MEXICO: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 300
TABLE 367 MEXICO: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 300
TABLE 368 MEXICO: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 300
TABLE 369 MEXICO: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 301
TABLE 370 MEXICO: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 301
TABLE 371 MEXICO: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2019–2022 (USD MILLION) 301
TABLE 372 MEXICO: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2023–2029 (USD MILLION) 302
TABLE 373 MEXICO: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2019–2022 (USD MILLION) 302
TABLE 374 MEXICO: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE,
2023–2029 (USD MILLION) 302
TABLE 375 MEXICO: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2019–2022 (USD MILLION) 303
TABLE 376 MEXICO: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2023–2029 (USD MILLION) 303
TABLE 377 MEXICO: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 304
TABLE 378 MEXICO: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 304
TABLE 379 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2022 (USD MILLION) 305
TABLE 380 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2023–2029 (USD MILLION) 305
TABLE 381 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET FOR CHICKEN,
BY TYPE, 2019–2022 (USD MILLION) 305
TABLE 382 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET FOR CHICKEN,
BY TYPE, 2023–2029 (USD MILLION) 306
TABLE 383 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT, 2019–2022 (USD MILLION) 306
TABLE 384 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 306
TABLE 385 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2019–2022 (USD MILLION) 307
TABLE 386 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2023–2029 (USD MILLION) 307
TABLE 387 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 307
TABLE 388 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 308
TABLE 389 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET,
BY DISEASE INDICATION, 2019–2022 (USD MILLION) 308
TABLE 390 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET,
BY DISEASE INDICATION, 2023–2029 (USD MILLION) 309
TABLE 391 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 309
TABLE 392 REST OF LATIN AMERICA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 309
TABLE 393 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET, BY REGION, 2019–2022 (USD MILLION) 310
TABLE 394 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET, BY REGION, 2023–2029 (USD MILLION) 310
TABLE 395 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2022 (USD MILLION) 310
TABLE 396 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2023–2029 (USD MILLION) 311
TABLE 397 MIDDLE EAST & AFRICA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 311
TABLE 398 MIDDLE EAST & AFRICA: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 311
TABLE 399 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY PRODUCT, 2019–2022 (USD MILLION) 312
TABLE 400 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY PRODUCT, 2023–2029 (USD MILLION) 312
TABLE 401 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2019–2022 (USD MILLION) 312
TABLE 402 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2023–2029 (USD MILLION) 313
TABLE 403 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES,
BY TYPE, 2019–2022 (USD MILLION) 313
TABLE 404 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET FOR VACCINES,
BY TYPE, 2023–2029 (USD MILLION) 313
TABLE 405 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY DISEASE INDICATION, 2019–2022 (USD MILLION) 314
TABLE 406 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY DISEASE INDICATION, 2023–2029 (USD MILLION) 314
TABLE 407 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 315
TABLE 408 MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 315
TABLE 409 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2019–2022 (USD MILLION) 317
TABLE 410 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2023–2029 (USD MILLION) 317
TABLE 411 GCC COUNTRIES: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2019–2022 (USD MILLION) 318
TABLE 412 GCC COUNTRIES: CHICKEN PHARMACEUTICALS MARKET, BY TYPE,
2023–2029 (USD MILLION) 318
TABLE 413 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2019–2022 (USD MILLION) 318
TABLE 414 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 319
TABLE 415 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2019–2022 (USD MILLION) 319
TABLE 416 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2023–2029 (USD MILLION) 319
TABLE 417 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 320
TABLE 418 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 320
TABLE 419 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2019–2022 (USD MILLION) 320
TABLE 420 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION, 2023–2029 (USD MILLION) 321
TABLE 421 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 321
TABLE 422 GCC COUNTRIES: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 321
TABLE 423 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY ANIMAL TYPE, 2019–2022 (USD MILLION) 322
TABLE 424 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY ANIMAL TYPE, 2023–2029 (USD MILLION) 323
TABLE 425 REST OF MIDDLE EAST & AFRICA: CHICKEN PHARMACEUTICALS MARKET,
BY TYPE, 2019–2022 (USD MILLION) 323
TABLE 426 REST OF MIDDLE EAST & AFRICA: CHICKEN PHARMACEUTICALS MARKET,
BY TYPE, 2023–2029 (USD MILLION) 323
TABLE 427 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY PRODUCT, 2019–2022 (USD MILLION) 324
TABLE 428 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY PRODUCT, 2023–2029 (USD MILLION) 324
TABLE 429 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET
FOR DRUGS, BY TYPE, 2019–2022 (USD MILLION) 324
TABLE 430 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET
FOR DRUGS, BY TYPE, 2023–2029 (USD MILLION) 325
TABLE 431 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET
FOR VACCINES, BY TYPE, 2019–2022 (USD MILLION) 325
TABLE 432 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET
FOR VACCINES, BY TYPE, 2023–2029 (USD MILLION) 325
TABLE 433 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY DISEASE INDICATION, 2019–2022 (USD MILLION) 326
TABLE 434 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY DISEASE INDICATION, 2023–2029 (USD MILLION) 326
TABLE 435 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2019–2022 (USD MILLION) 327
TABLE 436 REST OF MIDDLE EAST & AFRICA: POULTRY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2023–2029 (USD MILLION) 327
TABLE 437 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES 329
TABLE 438 POULTRY PHARMACEUTICALS MARKET: DEGREE OF COMPETITION 332
TABLE 439 POULTRY PHARMACEUTICALS MARKET: REGION FOOTPRINT 337
TABLE 440 POULTRY PHARMACEUTICALS MARKET: ANIMAL TYPE FOOTPRINT 338
TABLE 441 POULTRY PHARMACEUTICALS MARKET: PRODUCT FOOTPRINT 339
TABLE 442 POULTRY PHARMACEUTICALS MARKET: DISEASE INDICATION FOOTPRINT 340
TABLE 443 POULTRY PHARMACEUTICALS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 341
TABLE 444 POULTRY PHARMACEUTICALS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 344
TABLE 445 POULTRY PHARMACEUTICALS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 344
TABLE 446 POULTRY PHARMACEUTICALS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024 346
TABLE 447 POULTRY PHARMACEUTICALS MARKET: DEALS, JANUARY 2021−NOVEMBER 2024 347
TABLE 448 POULTRY PHARMACEUTICALS MARKET:
EXPANSIONS, JANUARY 2021−NOVEMBER 2024 348
TABLE 449 POULTRY PHARMACEUTICALS MARKET:
OTHER DEVELOPMENTS, JANUARY 2021−NOVEMBER 2024 348
TABLE 450 MERCK ANIMAL HEALTH: COMPANY OVERVIEW 349
TABLE 451 MERCK ANIMAL HEALTH: PRODUCTS OFFERED 350
TABLE 452 ELANCO: COMPANY OVERVIEW 353
TABLE 453 ELANCO: PRODUCTS OFFERED 354
TABLE 454 ELANCO: DEALS, JANUARY 2021–NOVEMBER 2024 355
TABLE 455 ELANCO: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 356
TABLE 456 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 357
TABLE 457 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 358
TABLE 458 BOEHRINGER INGELHEIM INTERNATIONAL GMBH:
PRODUCT APPROVALS, JANUARY 2021– NOVEMBER 2024 359
TABLE 459 BOEHRINGER INGELHEIM INTERNATIONAL GMBH:
DEALS, JANUARY 2021– NOVEMBER 2024 359
TABLE 460 BOEHRINGER INGELHEIM INTERNATIONAL GMBH:
EXPANSIONS, JANUARY 2021– NOVEMBER 2024 360
TABLE 461 CEVA SANTÉ ANIMALE: COMPANY OVERVIEW 361
TABLE 462 CEVA SANTÉ ANIMALE: PRODUCTS OFFERED 361
TABLE 463 ZOETIS SERVICES LLC: COMPANY OVERVIEW 363
TABLE 464 ZOETIS SERVICES LLC: PRODUCTS OFFERED 364
TABLE 465 ZOETIS SERVICES LLC: JANUARY 2021–NOVEMBER 2024 366
TABLE 466 ZOETIS SERVICES LLC: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 366
TABLE 467 ZOETIS SERVICES LLC: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024 366
TABLE 468 VIRBAC: COMPANY OVERVIEW 368
TABLE 469 VIRBAC: PRODUCTS OFFERED 369
TABLE 470 VIRBAC: DEALS, JANUARY 2021– NOVEMBER 2024 370
TABLE 471 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY OVERVIEW 371
TABLE 472 PHIBRO ANIMAL HEALTH CORPORATION: PRODUCTS OFFERED 372
TABLE 473 PHIBRO ANIMAL HEALTH CORPORATION:
DEALS, JANUARY 2021– NOVEMBER 2024 374
TABLE 474 HESTER BIOSCIENCES LIMITED: COMPANY OVERVIEW 375
TABLE 475 HESTER BIOSCIENCES LIMITED: PRODUCTS OFFERED 376
TABLE 476 HESTER BIOSCIENCES LIMITED: DEALS, JANUARY 2021–NOVEMBER 2024 378
TABLE 477 MEIJI ANIMAL HEALTH CO., LTD.: COMPANY OVERVIEW 379
TABLE 478 MEIJI ANIMAL HEALTH CO., LTD.: PRODUCTS OFFERED 380
TABLE 479 VENKY’S INDIA: COMPANY OVERVIEW 382
TABLE 480 VENKY’S INDIA: PRODUCTS OFFERED 383
TABLE 481 BIMEDA CORPORATE: COMPANY OVERVIEW 386
TABLE 482 BIMEDA CORPORATE: PRODUCTS OFFERED 386
TABLE 483 CALIER: COMPANY OVERVIEW 388
TABLE 484 CALIER: PRODUCTS OFFERED 388
TABLE 485 HIPRA: COMPANY OVERVIEW 390
TABLE 486 HIPRA: PRODUCTS OFFERED 391
TABLE 487 VETANCO: COMPANY OVERVIEW 392
TABLE 488 VETANCO: PRODUCTS OFFERED 392
TABLE 489 VAXXINOVA INTERNATIONAL BV: COMPANY OVERVIEW 394
TABLE 490 VAXXINOVA INTERNATIONAL BV: PRODUCTS OFFERED 394
TABLE 491 BIOVAC GROUP: COMPANY OVERVIEW 396
TABLE 492 BIOVAC GROUP: PRODUCTS OFFERED 396
TABLE 493 KEMIN INDUSTRIES, INC.: COMPANY OVERVIEW 399
TABLE 494 KEMIN INDUSTRIES, INC.: PRODUCTS OFFERED 399
TABLE 495 О.L.KAR.-AGROZOOVET-SERVICE: COMPANY OVERVIEW 401
TABLE 496 О.L.KAR.-AGROZOOVET-SERVICE: PRODUCTS OFFERED 401
TABLE 497 INDOVAX: COMPANY OVERVIEW 404
TABLE 498 INDOVAX: PRODUCTS OFFERED 405
TABLE 499 AVIMEX: COMPANY OVERVIEW 406
TABLE 500 AVIMEX: PRODUCTS OFFERED 406
LIST OF FIGURES
FIGURE 1 MARKET & REGIONAL SEGMENTATION 36
FIGURE 2 RESEARCH DESIGN 39
FIGURE 3 PRIMARY SOURCES 41
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS:
SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 43
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 44
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE):
BY END USER, DESIGNATION, AND REGION 44
FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 45
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: MERCK ANIMAL HEALTH (2023) 46
FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION:
POULTRY PHARMACEUTICALS MARKET (2023) 47
FIGURE 10 MARKET SIZE ESTIMATION: DEMAND ANALYSIS 48
FIGURE 11 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES ANALYSIS (2023–2029) 49
FIGURE 12 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 50
FIGURE 13 DATA TRIANGULATION METHODOLOGY 51
FIGURE 14 POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024 VS. 2029 (USD MILLION) 54
FIGURE 15 POULTRY PHARMACEUTICALS MARKET, BY PRODUCT,
2024 VS. 2029 (USD MILLION) 55
FIGURE 16 POULTRY PHARMACEUTICALS MARKET, BY DISEASE INDICATION,
2024 VS. 2029 (USD MILLION) 55
FIGURE 17 POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION,
2024 VS. 2029 (USD MILLION) 56
FIGURE 18 GEOGRAPHIC SNAPSHOT OF POULTRY PHARMACEUTICALS MARKET 57
FIGURE 19 INCREASING POULTRY CONSUMPTION TO PROPEL MARKET 58
FIGURE 20 VACCINES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 59
FIGURE 21 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 60
FIGURE 22 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD 60
FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES
DURING FORECAST PERIOD 61
FIGURE 24 POULTRY PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 62
FIGURE 25 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING
MANUFACTURING PHASE 68
FIGURE 26 POULTRY PHARMACEUTICALS MARKET SUPPLY CHAIN ANALYSIS 69
FIGURE 27 POULTRY PHARMACEUTICALS MARKET: PORTER’S FIVE FORCES ANALYSIS 72
FIGURE 28 PATENT PUBLICATION TRENDS (JANUARY 2014–SEPTEMBER 2024) 78
FIGURE 29 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES)
FOR POULTRY PHARMACEUTICALS (JANUARY 2014–SEPTEMBER 2024) 78
FIGURE 30 TOP APPLICANT JURISDICTIONS FOR POULTRY PHARMACEUTICAL PATENTS (JANUARY 2014–SEPTEMBER 2024) 79
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR DRUGS,
VACCINES, AND FEED ADDITIVES 85
FIGURE 32 KEY BUYING CRITERIA FOR DRUGS, VACCINES, AND FEED ADDITIVES 85
FIGURE 33 POULTRY PHARMACEUTICALS MARKET: END-USER EXPECTATIONS 88
FIGURE 34 POULTRY PHARMACEUTICALS MARKET: ECOSYSTEM MARKET MAP 90
FIGURE 35 ADJACENT MARKETS OF POULTRY PHARMACEUTICALS MARKET 92
FIGURE 36 INVESTMENT/VENTURE CAPITAL SCENARIO IN POULTRY PHARMACEUTICALS MARKET, 2019–2022 92
FIGURE 37 POULTRY PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT (2024–2029) 186
FIGURE 38 NORTH AMERICA: POULTRY PHARMACEUTICALS MARKET SNAPSHOT 188
FIGURE 39 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET SNAPSHOT 246
FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN POULTRY PHARMACEUTICALS MARKET (2019−2023) 330
FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN POULTRY PHARMACEUTICALS MARKET (2023) 331
FIGURE 42 POULTRY PHARMACEUTICALS MARKET:
COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 335
FIGURE 43 POULTRY PHARMACEUTICALS MARKET: COMPANY FOOTPRINT 336
FIGURE 44 POULTRY PHARMACEUTICALS MARKET:
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 343
FIGURE 45 EV/EBITDA OF KEY VENDORS 345
FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND
5-YEAR STOCK BETA OF KEY VENDORS 345
FIGURE 47 POULTRY PHARMACEUTICALS MARKET:
BRAND/PRODUCT COMPARATIVE ANALYSIS 346
FIGURE 48 MERCK & CO., INC.: COMPANY SNAPSHOT (2023) 350
FIGURE 49 ELANCO: COMPANY SNAPSHOT (2023) 354
FIGURE 50 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2023) 358
FIGURE 51 ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2023) 364
FIGURE 52 VIRBAC: COMPANY SNAPSHOT (2023) 369
FIGURE 53 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2023) 372
FIGURE 54 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT (2023) 376
FIGURE 55 MEIJI ANIMAL HEALTH CO., LTD.: COMPANY SNAPSHOT (2023) 379
FIGURE 56 VENKY’S INDIA: COMPANY SNAPSHOT (2023) 383
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11